Repotrex 40 mg | Generic Repotrectinib by Everest Pharmaceuticals

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.

Is Repotrex 40 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)
✓Adult or paediatric (12+) NTRK gene fusion-positive solid tumours, unresectable or metastatic
✓TKI-naïve or previously treated with another ROS1/TRK inhibitor
✓Need a WHO-GMP generic alternative to Augtyro® (Bristol Myers Squibb)

✖ May NOT be suitable if

✗ROS1 or NTRK fusion not confirmed by validated molecular testing
✗Pre-existing significant interstitial lung disease
✗Pregnant, planning pregnancy, or breastfeeding
✗Significant hepatic impairment without dose adjustment

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Repotrex 40 mg?

Repotrex 40 mg is a generic formulation of Repotrectinib — a next-generation, macrocyclic tyrosine kinase inhibitor (TKI) — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each capsule contains 40 mg of repotrectinib, the same active molecule found in Augtyro® (Bristol Myers Squibb), and is dispensed under the Named Patient Program.

Repotrectinib’s macrocyclic (ring-shaped) structure is smaller and more compact than earlier ROS1/TRK inhibitors, allowing it to maintain binding against several resistance mutations that commonly cause other TKIs to lose effectiveness — and to cross the blood-brain barrier effectively, an important feature given how often ROS1+ NSCLC spreads to the brain.

Generic name	Repotrectinib
Reference brand	Augtyro® (Bristol Myers Squibb)
Manufacturer	Everest Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	ROS1/TRK Inhibitor (macrocyclic TKI)
Dosage form	Capsule — 40 mg
Route	Oral · once or twice daily depending on treatment phase
Prescription	Required — oncologist only

How Repotrectinib Works

ROS1 gene rearrangements and NTRK gene fusions drive uncontrolled tumour growth by producing permanently active fusion proteins. Repotrectinib selectively inhibits the resulting abnormal ROS1 and TRK kinase activity.

In the pivotal TRIDENT-1 trial, repotrectinib demonstrated robust anti-tumour activity with high response rates in both TKI-naïve and TKI-pretreated ROS1-positive NSCLC patients. Its compact macrocyclic structure was specifically engineered to retain activity against solvent-front and other resistance mutations that commonly develop after treatment with earlier ROS1 inhibitors such as crizotinib or entrectinib. Strong CNS penetration makes it a particularly relevant option for patients with brain metastases, which are common in ROS1-rearranged lung cancer.

What to Expect: First 30 Days

Week 1–2: Treatment starts at 160 mg once daily. Dizziness and taste changes (dysgeusia) are common early side effects — your oncologist may advise on positional changes to reduce dizziness (e.g. rising slowly from sitting/lying).
Day 15 onward: If the initial dose is well tolerated, the dose typically increases to 160 mg twice daily, per your oncologist’s specific protocol.
Weeks 3–4: Peripheral neuropathy (tingling/numbness in hands or feet) and constipation may develop. Your oncologist will monitor for signs of interstitial lung disease and liver function changes at scheduled visits.

Side Effects

Common · Usually Manageable

Dizziness
Dysgeusia (taste changes)
Peripheral neuropathy
Constipation
Fatigue
Dyspnoea (mild)

Serious · Report Immediately

CNS effects (severe dizziness, cognitive changes)
Interstitial lung disease (ILD) / pneumonitis
Hepatotoxicity
QT interval prolongation

⚠ Call your doctor immediately if you experience:

New or worsening breathlessness, cough, or fever (possible ILD)
Severe dizziness, confusion, or difficulty with balance/coordination
Yellowing of skin or eyes (possible liver injury)

How to Take Repotrex 40 mg

Initial dose: 160 mg once daily for the first 14 days — then, if tolerated, increased to 160 mg twice daily. Always follow your oncologist’s specific prescription and titration schedule.

1
Follow the exact titration schedule your oncologist prescribes — do not increase the dose yourself even if you feel well.
2
Swallow capsules whole with water. Can be taken with or without food.
3
Be cautious with activities requiring alertness (driving, operating machinery) until you know how dizziness affects you.
4
Storage: room temperature, dry place, out of reach of children.

If the Medicine Stops Working

Resistance to repotrectinib can develop through secondary mutations in the ROS1 or TRK kinase domain, or through activation of alternative signalling pathways bypassing the original driver mutation. If disease progression is detected, your oncologist will typically order repeat molecular testing (tissue or liquid biopsy) to characterise the resistance mechanism and determine the next treatment strategy, which may include chemotherapy, a different targeted agent, or clinical trial enrolment.

Frequently Asked Questions

Is Repotrex the same as Augtyro?

Yes — Repotrex contains the exact same active ingredient, repotrectinib, as Augtyro. It is manufactured by Everest Pharmaceuticals to WHO-GMP certified standards, ensuring the same clinical mechanism at a significantly lower cost than the branded product.

Do I need genetic testing before starting Repotrex?

Yes. Repotrectinib is only appropriate for patients with a confirmed ROS1 gene rearrangement or NTRK gene fusion, identified through validated molecular testing on tumour tissue or a blood-based liquid biopsy. Your oncologist will confirm this before prescribing.

Why does the dose change after 2 weeks?

The approved dosing schedule starts at a lower dose (160 mg once daily) for the first 14 days to assess tolerability, then increases to the target maintenance dose (160 mg twice daily) if the starting dose is well tolerated. This step-up approach reduces the risk of severe early side effects.

Can Repotrex treat brain metastases?

Repotrectinib was specifically engineered with strong CNS (central nervous system) penetration, making it effective against brain metastases that are common in ROS1-positive NSCLC. This is a key clinical advantage over some earlier-generation ROS1 inhibitors.

How do I order Repotrex through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription confirming ROS1 or NTRK fusion status. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

Clinical References

Drilon A, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer (TRIDENT-1). NEJM 2024;390:118–131.
FDA Prescribing Information: Augtyro (repotrectinib). Bristol Myers Squibb, 2023.